Invivyd Reports Q3 2024 Preliminary Results With $9.3M PEMGARDA Revenue, Withdraws Guidance Amid FDA Headwinds, And Targets Profitability In 2025
Portfolio Pulse from Benzinga Newsdesk
Invivyd reported preliminary Q3 2024 results with $9.3M in PEMGARDA revenue and $107M in cash. The company withdrew revenue guidance due to FDA warnings and aims for profitability in 2025.
October 29, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Invivyd reported $9.3M in Q3 2024 revenue for PEMGARDA but withdrew guidance due to FDA warnings. The company aims for profitability in 2025.
The withdrawal of revenue guidance due to FDA warnings is a negative signal for investors, indicating potential challenges in product performance and regulatory hurdles. However, the company's target for profitability in 2025 provides a long-term positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100